Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for Cognitive Control in Adult ADHD
NCT03136263Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2017
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Stop-signal task performance. Started Dec 2017; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03136263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136263.